Aims: While pharmacological glucagon-like peptide-1 receptor (GLP-1R) agonists are FDAapproved for treating type 2 diabetes mellitus (T2DM) and obesity, a major side effect is nausea/malaise. We recently developed a conjugate of vitamin B12 (B12) bound to the GLP-1R agonist exendin-4 (Ex4), which displays enhanced proteolytic stability and retention of GLP-1R agonism. Here, we evaluate whether the conjugate (B12-Ex4) can improve glucose tolerance without producing anorexia and malaise.
| INTRODUCTION
Multiple incretin-based therapeutics are approved for the treatment of type 2 diabetes mellitus (T2DM) because of their ability to elicit pancreatic insulin secretion and reduce blood glucose levels. These pharmacotherapies include compounds designed to increase endogenous concentrations of the incretin hormone glucagon-like peptide-1 (GLP-1) by inhibiting the endopeptidase DPP-IV, as well as synthetic peptide-based GLP-1 receptor (GLP-1R) agonists resistant to DPP-IV degradation. 1 In addition to being the more potent class of GLP-1-based therapeutics for reducing glycaemia, GLP-1R agonists significantly reduce food intake and body weight in both humans and animal models. [1] [2] [3] This anorectic effect is attractive when considering the utilization of GLP-1R agonists as an on-or off-label treatment option for obesity, and indeed, the GLP-1R agonist liraglutide is FDA-approved for the treatment of obesity. 4 However, a sizeable percentage of individuals with T2DM does not have obesity or overweight [5] [6] [7] and may want to avoid weight loss. Furthermore, it is important to note that the hypophagic effects of GLP-1R agonists are accompanied by a pronounced incidence of nausea, vomiting and malaise. 3, 8, 9 In fact, 20% to 50% of T2DM patients receiving GLP-1-based medication experience nausea and/or vomiting, leading to discontinuation of drug treatment in~6% to 10% and reduced dose tolerance in another 15%. [10] [11] [12] [13] [14] These adverse effects are surprisingly under-investigated, cell-derived GLP-1. [16] [17] [18] Importantly, activation of GLP-1R expressed on vagal afferent fibers and/or in discrete nuclei in the central nervous system (CNS) also contributes to exogenous GLP-1R agonistmediated improvements in glycaemic control. [1] [2] [3] 15, [19] [20] [21] Interestingly, these dual sites of action (ie, vagal and direct CNS activation) also mediate the intake-and body weight-suppressive effects of exogenous systemic GLP-1R agonist administration. [21] [22] [23] Both liraglutide and exenatide can penetrate into the CNS and activate central GLP-1R-expressing nuclei, leading to hypophagia and weight loss. 22, 24 Remarkably, however, GLP-1R agonist-induced illness behaviors (eg, nausea, conditioned taste avoidance, hypophagia, emesis) are mediated by GLP-1Rs expressed within the CNS and not by vagal afferent GLP-1Rs when these compounds are delivered systemically. 8 Although other T2DM medications (eg, DPP-IV inhibitors) may improve glycaemic control with minimal effects on energy balance, 25, 26 long-lasting GLP-1R agonists provide several advantages, such as improved glycaemic control and less frequent administration. 27 in mouse models with over 5% ID/g observed in pancreas. 40 We therefore hypothesized that a B12-Ex4 conjugate would retain the incretin profile of a GLP-1R agonist to improve glucose tolerance, but would prevent development of nausea/malaise through reduced, or redirected, CNS/hypothalamic penetration of the agonist.
The rat is a unique animal model for pre-clinical testing of the B12-Ex4 conjugate. Rats, unlike humans and mice, demonstrate an unexpected hyperglycaemic response to systemic Ex4 delivery. This hyperglycaemic effect is unique to the Ex4 molecule (among approved GLP-1R agonists) in the rat and is explained, in part, by CNS-mediated sympathetic activation. 41 Further, rats show welldocumented hypophagic effects to GLP-1R ligands, mediated partly by accompanying acute effects on nausea/malaise, similar to humans, but not to mice. 8, 9 Rats were therefore used as the primary model to evaluate the effects of B12-Ex4 on glycaemic control, energy balance and nausea/malaise, and these effects were compared with the response profile after peripheral administration of unconjugated Ex4.
Given that Ex4 produces hypoglycaemic effects in mice, 42, 43 similar to the effect observed in humans, 44, 45 blood glucose levels in mice
were assessed also in a glucose tolerance test (GTT) upon B12-Ex4 or Ex4 administration. The data presented here provide evidence for second-generation "cobalaminylated" GLP-1R agonists for the treatment of T2DM, with a pronounced profile of effects that include glucoregulation without anorexia or body weight loss, and most critically, an absence of nausea/malaise. 
| MATERIALS AND METHODS

| Animals
| Compounds
B12-conjugated exendin-4 (B12-Ex4) was produced, characterized and screened for agonism at the GLP-1R (EC 50 of 68 pM, relative to 28 pM for Ex4 in the same assay), as previously described. 30 One addition to the characterization was the measure of TCII binding of B12-Ex4 ( Figure 1D ), which was conducted at the Department of Clin- tions were administered using a within-subjects, Latin square design.
The exception was the conditioned taste avoidance (CTA) study, which used a between-subjects design.
| Effects of B12-Ex4 on energy balance
Shortly before onset of the dark phase, rats (n = 12) received subcutaneous (SC) injection of B12-Ex4 (1, 5 or 20 μg/kg) or vehicle (1 mL/ kg sterile saline). Chow intake was measured at 1, 3, 6 and 24 hours post-injection. Food spillage was accounted for in all intake measurements. Body weight was also measured at 0 and 24 hours.
| Effects of B12-Ex4 on glycaemic control during oral glucose tolerance test (OGTT)
Rats (n = 12) were deprived of food overnight before testing. On the morning of testing, just after onset of the dark phase, water was also removed from the cage. A small drop of blood was collected from the tail tip and was analysed for blood glucose (BG) level using a standard glucometer (AccuCheck). Immediately after this baseline BG reading , consistent with conjugate containing 2 molecules of Cy5 per B12-Ex4 component. G, Excitation and emission spectra of Cy5-B12-Ex4 at 648 and 670 nm, respectively. H, Cy5-B12-Ex4 agonism at the GLP-1 receptor reported using the FRET reporter H188; EC 50 = 13 nM. Note that B12-Ex4 agonism at the GLP-1 receptor was previously reported (68 pM) 30 
| Effects of systemic Ex4 on glycaemic control and energy balance
The effects of unconjugated Ex4 were evaluated in an OGTT, using methods similar to those described above, with 2 major differences: SC injections were Ex4 (5 or 20 μg/kg) or vehicle (1 mL/kg sterile saline), and food intake and body weight change after completion of the OGTT were monitored. Pre-weighed food was returned to the rats after the OGTT, and chow intake was measured for~21.5 hours (eg, until 24 hours after the SC injections). Spillage was accounted for in food intake measurements. Body weight was recorded at 0 and 24 hours. For the OGTT, rats (n = 10) were tested; food and body weight data were collected with 1 less rat included (n = 9) following a technical error in food intake measurement.
| Effects of B12-Ex4 on expression of a conditioned taste avoidance (CTA)
Rats (n = 8-10 per drug) were evaluated for expression of a CTA to a flavour paired with B12-Ex4 (5 μg/kg, IP). Ex4 (5 μg/kg, IP) and LiCl (0.15 M) were used as positive controls. A 2-bottle test was used so each rat had access to a flavour that had been paired previously with vehicle (1 mL/kg saline, IP) and a flavour that had been paired previously with drug (B12-Ex4, Ex4 or LiCl). See Appendix S1 for more details.
| Effect of B12-Ex4 on glycaemic control in mice during intraperitoneal glucose tolerance test (IPGTT)
The experimental procedure for IPGTT in mice was similar to that used for OGTT in rats. Briefly, mice (n = 13; 8 females, 5 males) were food-and water-deprived for 4 hours before and during the IPGTT.
Testing was completed at the mid-light phase. Blood was collected from the tail tip and was analysed for BG. Immediately after this baseline reading (t = −30 minutes), each mouse received IP injection of Ex4 (5 μg/kg), B12-Ex4 (equimolar dose to Ex4) or saline (10 μL/g).
BG was measured 30 minutes later (t = 0 minutes) and each mouse received IP injection of glucose (2 g/kg). Subsequent BG readings were taken at 20, 40, 60 and 120 minutes after glucose injection.
After the final BG reading, food and water were returned. Area under the curve (AUC) was calculated from 0 to 120 minutes (eg, beginning at the time of glucose administration) using the trapezoidal method.
| B12-Exendin-4-Cyanine-5 (Cy5-B12-Ex4) synthesis
B12-Ex4 was synthesized as described previously.
30 B12-Ex4
(0.5 mg, 0.0001 mmol) was dissolved in PBS buffer pH 7.6 (450 μL)
and sulfo-cyanine5-NHS-ester (1 mg, 0.001 mmol) (Lumiprobe) was added (in 50 μL DMSO). The resulting solution was allowed to mix for 2 hours at room temperature, protected from light, and was then purified through RP-HPLC on a Shimadzu Prominence HPLC using a C18 column (Eclipse XDB-C18 5 μm, 4.6 × 150 mm 
| GLP-1 assay for Cy5-B12-Ex4
Agonism at the GLP-1 receptor was monitored using HEK-293 cells Appendix S1 for more detail.
To evaluate penetrance of B12-Ex4 in the pancreas, rats (n = 2)
were given IP injection of Cy5-B12-Ex4 (5 μg/kg) and were transcardially perfused 3 hours later with 4% paraformaldehyde in PBS. Pancreases were collected and sagittally sectioned, processed via immunohistochemistry for insulin and coverslipped with DAPI mounting medium. Sections were visualized with confocal microscopy and 3-dimensional rotational animations were rendered from the collected z-stack images using Imaris 8.1.2 (Bitplane, Zurich, Switzerland). See Appendix S1 for more detail.
| Statistical analyses
See Appendix S1.
3 | RESULTS 3.1 | B12-Ex4 has potent beneficial effects on glycaemic control, but minimal impact on feeding and body weight in rats
Ex4 and other GLP-1R agonists reduce blood glucose levels, and are used clinically to treat T2DM. 52 In addition, the food intake-and body weight-suppressive effects of GLP-1R agonists have highlighted the utility of these pharmacotherapies for treatment of obesity. 53 To evaluate whether the metabolic effects of B12-Ex4 are similar to those of other GLP-1R agonists such as unconjugated Ex4, the effects of SC injection of B12-Ex4 on energy balance and glycaemic control were evaluated. To confirm TCII binding of B12 in its Ex4 conjugated form (ie, B12-Ex4), a radio chase assay using 57 Co-labelled B12 was conducted, 46 and confirmed low nanomolar binding (~75 nM) was maintained ( Figure 1D ).
First, to test whether B12-Ex4 has intake-and body weightsuppressive effects similar to those of Ex4, rats were given SC injection of B12-Ex4 (0, 1, 5 or 20 μg/kg in 1 mL/kg sterile saline), and subsequent food intake (1, 3, 6, 24 hours) and body weight gain were measured. The highest dose of B12-Ex4, 20 μg/kg, significantly suppressed food intake at 3 and 6 hours post injection (Figure 2A) (drug × time interaction, F 9,99 = 3.69, P < .001; 0 vs 20 μg/kg, P < .05 at 3 and 6 hours). No other significant effects on food intake were observed, at other times or with other doses of drug (all other P > .05). There was also no significant effect of B12-Ex4 on 24-hour body weight change ( Figure 2B ) (F 3,33 = 0.50, P = .69), which is consistent with the fact that cumulative 24-hour energy intake was similar among the treatment conditions. is also suggested by the finding that 20 μg/kg B12-Ex4 had more potent BG-suppressive effects than 5 μg/kg at 20 minutes after glucose gavage (P < .05). Interestingly, BG levels were increased by both doses of B12-Ex4 at 60 minutes and by the higher dose at 120 minutes (all P < .05). Importantly, injection of B12-Ex4 had no effect on blood glucose levels on its own (t = 0 minutes, all P > .05). 
| Systemic injection of Ex4 produces hyperglycaemia, hypophagia and weight loss
The rat is a particularly interesting model to test the effects of an Ex4-based drug on glycaemic and energy balance control, because rats exhibit a hyperglycaemic response to acute peripheral administration of Ex4 as a result of sympathetic activation, 41 but they also show pronounced reductions in feeding and body weight gain. [54] [55] [56] To evaluate the effects of SC administration of unconjugated Ex4 on these measures, and to be able to more directly compare the effects of B12-Ex4 to those of Ex4, an OGTT was administered to rats after SC injection of Ex4 (5 or 20 μg/kg) or vehicle (1 mL/kg), and subsequent chow intake and body weight were monitored after the OGTT.
Similar to previous findings, 41 systemic Ex4 produced a pronounced hyperglycaemic response in the rats ( Figure 3A ) (main effect of drug, F 2,18 = 8.84, P < .01; drug x time interaction, F 10,90 = 11.89, P < .000001). Injection of either dose of Ex4 increased BG on its own (eg, before administration of glucose; at t = 0 minutes, vehicle vs 5 or 20 μg/kg, P < .05). BG levels remained significantly elevated in Ex4-treated rats at 40, 60 and 120 minutes after glucose gavage (vehicle vs 5 or 20 μg/kg, all P < .05).
When food was returned after the last BG reading, Ex4-treated rats ate significantly less than did vehicle-treated controls in the subsequent 21.5 hours ( Figure 3B ) (F 2,16 = 43.74, P < .000001; vehicle vs 5 or 20 μg/kg, P < .05) and gained less body weight ( Figure 3C ) (F 2,16 = 8.31, P < .01; vehicle vs 20 μg/kg, P < .05). These results demonstrate the unique constellation of effects produced by peripheral Ex4 administration in the rat and, more importantly, highlight the distinct differences between Ex4 and B12-Ex4 for glycaemic and energy balance control.
| Ex4 elicits expression of a robust CTA that is not observed with B12-Ex4
GLP-1R agonists such as Ex4 have undesired side effects including nausea/malaise. 8, 52 To evaluate whether B12-Ex4 produces nausea/ malaise, rats were evaluated for expression of a conditioned taste avoidance (CTA) to B12-Ex4 (5 μg/kg, IP). Additional groups of rats were evaluated in this experiment for CTA to Ex4 (5 μg/kg, IP) or to LiCl (0.15 M, IP), which is well known to produce nausea and CTA in rodents. 8, 57, 58 As shown in Figure 3D , acceptance of the drug-paired flavour was significantly higher in the B12-Ex4-treated group compared to either LiCl or Ex4 (F 2,24 = 5.29, P < .01; B12-Ex4 vs LiCl or Ex4, P < .05; LiCl vs Ex4, P > .05), suggesting that B12-Ex4 does not produce the same nausea/malaise as Ex4.
| In mice, B12-Ex4 and Ex4 suppress blood glucose levels in a glucose tolerance test
To confirm the ability of B12-Ex4 to improve glycaemic control in species that do not exhibit Ex4-induced stress-mediated hyperglycaemic responses, the glycaemic effects of equimolar doses of B12-Ex4 and Ex4 were tested via IPGTT in mice. In contrast to rats, and more in line with human data, 44, 45 Ex4 administration strongly attenuated the increase in blood glucose levels after IP glucose administration.
Similarly, B12-Ex4 reduced blood glucose levels in the IPGTT ( Figure 4A ) (main effect of drug, F 2,24 = 67.13, P < .0001; drug × time interaction, F 10,120 = 15.07, P < .0001). Posthoc analyses showed that both compounds significantly suppressed BG at 20, 40, 60 and 120 minutes after glucose injection (all P < .05). Interestingly, injection of B12-Ex4 or Ex4 also reduced BG levels prior to IP glucose injection (t = 0, all P < .05). Although Ex4 had a more potent effect on BG at 20 minutes, compared to B12-Ex4 (P < .05), area under the curve analyses revealed that both compounds had hypoglycaemic effects post-glucose load compared to saline ( Figure 4B) (F 2,24 = 62.74, P < .0001; vehicle vs B12-Ex4 or vs Ex4, P < .05).
| Unlike Ex4, B12-Ex4 does not readily penetrate into the CNS
Previous work shows that Ex4 crosses the blood-brain barrier to exert effects on energy balance and illness/malaise. 22, 31, 51 As B12-Ex4 treatment produces the glycaemic benefits associated with Ex4 without producing the centrally-mediated effects of hypophagia and nausea, this suggests that B12-Ex4 may be excluded from the CNS.
To evaluate this possibility, rats were treated systemically with a fluorescent-tagged version of B12-Ex4 (Cy5-B12-Ex4), and penetrance into the brain was evaluated using confocal microscopy. The results were compared with CNS penetrance of a fluorescenttagged version of Ex4 (Flex), which has been shown to penetrate into the CNS, 51 and fluorescent-tagged B12 (Cy5-B12). The presence of each of these fluorescent compounds was evaluated in the dorsal vagal complex (DVC) ( Figure 5 ) and paraventricular nucleus of the hypothalamus (PVN) (Figure 6) , because of the known importance of these areas in mediating the feeding effects of GLP-1R activation 59, 60 and the hyperglycaemic response observed in rats after systemic Ex4. 41 Consistent with previous data, 51 Flex was observed in the DVC, and was observed also within the PVN. In contrast, Cy5-B12 and Cy5-B12-Ex4 were not detected in either nucleus, suggesting that exogenously-injected B12 does not readily penetrate into these regions of the CNS and, hence, that conjugation of B12 to Ex4 greatly reduces or prevents Ex4 from entering the same areas.
| B12-Ex4 is colocalized on insulin-producing pancreatic beta cells
The finding that peripherally administered B12-Ex4 is not detected in the DVC or PVN suggests that the glycaemic effects of the compound are probably mediated via peripheral actions. The pancreas is a prime candidate for a peripheral site of action being responsible for the glycaemic-suppressive effects of B12-Ex4.
Indeed, GLP-1R agonists can act directly on pancreatic beta cells to stimulate insulin release, thereby improving blood glucose levels. [61] [62] [63] To assess whether B12-Ex4 is taken up by insulinproducing pancreatic beta cells, rats were given systemic injection of Cy5-B12-Ex4 (5 μg/kg) and colocalization with insulin-expressing cells was analysed in the pancreas with 3-dimensional confocal microscopy. Results show robust colocalization of Cy5-B12-Ex4 with insulin in pancreatic sections ( Figure 7 ) (Videos S1 and S2), supporting the hypothesis that B12-Ex4 acts at the pancreas to improve glycaemic control. The rat provides a unique model for the proof-of-concept testing needed for preclinical evaluation of B12-Ex4. Rats show an unexpected hyperglycaemic response to Ex4, explained, in part, by a CNSmediated activation of the sympathetic nervous system. 41 In addition, as humans, rats show a pronounced profile of behavioral effects to systemic Ex4, including reduced food intake and body weight, as well as illness-like behaviors, again explained by CNS action. reduces CNS Ex4 access. It will also be important to address whether higher doses of B12-Ex4 are able to more effectively penetrate the CNS. The 5 μg/kg dose of Cy5-B12-Ex4 used for this study was selected because 5 μg/kg B12-Ex4 had no effect on feeding or body weight in rats, but produced hypoglycaemia in the OGTT, suggesting that a lower dose of B12-Ex4 elicits an optimal profile of glycaemic and energy balance effects. In contrast, a higher dose of B12-Ex4 (20 μg/kg) reduced blood glucose but also caused a small but significant transient suppression of feeding, suggesting FIGURE 7 Systemically-delivered Cy5-B12-Ex4 is colocalized with insulin in the pancreas. The representative still images from 3-dimensional rotational videos (Videos S1 and S2) demonstrate that Cy5-B12-Ex4 (yellow) is colocalized with insulin (red) in pancreatic beta cells. Sections were counterstained with DAPI (blue). A, Videos and corresponding representative images were taken from a z-stack (2 μm step size) at 20× (Video S1) and B, from a z-stack (1μm step size) at 40× with 4-5× optical zoom (Video S2) that higher doses may have a slightly different pattern of effects.
Nevertheless, these results clearly underscore the reduced CNS penetrance, but retention of glycaemic benefits, with lower doses of B12-Ex4. 
